

1 Calf Raise Exercise Increases Walking Performance in Patients With Intermittent Claudication

2

3 Michel Van Schaardenburgh\* MD <sup>a</sup>, Martin Wohlwend MSc <sup>a</sup>, Øivind Rognmo PhD <sup>a</sup>, Erney

4 Mattsson MD PhD <sup>a, b</sup>

5 <sup>a</sup> Department of Circulation and Medical Imaging, Norwegian University of Science and

6 Technology, Trondheim, Norway

7 <sup>b</sup> Department of Vascular Surgery, St. Olavs Hospital, Trondheim, Norway

8

9 \* Corresponding author:

10 Michel van Schaardenburgh

11 Department of Circulation and Medical Imaging, Norwegian University of Science and

12 Technology, PO box 8905, 7491 Trondheim, Norway. E-mail

13 michel.van.schaardenburgh@ntnu.no

14

15 ABSTRACT

16 Background/Objective: Symptoms of intermittent claudication (IC) are improved by exercise.

17 The improvement might be secondary to increased blood perfusion or increased muscular

18 mitochondrial capacity. Ischemia followed by reperfusion, also named preconditioning, is known

19 to stimulate the mitochondria. We focused on a calf raise exercise inducing preconditioning in

20 the calf muscle of patients with IC. We hypothesized that eight weeks with this exercise would

21 increase walking performance and mitochondrial capacity without a change in blood flow.

22 Methods: Patients with IC were randomized to either a calf raise exercise (n=14) or a traditional

23 walking exercise group (n=15) The calf raise group was instructed to perform a specific type of

1 calf raise exercise three times a day. The walking group was instructed to walk near the pain  
2 threshold at least 30 minutes three times a week. Both interventions lasted eight weeks and were  
3 not supervised. Measurements of walking performance, mitochondrial capacity, peak oxygen  
4 uptake, peripheral hemodynamics and health-related quality of life were obtained on each patient  
5 before and after the intervention period. Adherence was measured by a training diary and an  
6 activity monitor was used.

7 Results: The calf raise group improved pain free walking distance by 44 meters ( $P=.04$ ) and  
8 maximal walking distance by 99 meters ( $P=.047$ ). Furthermore, claudication onset time  
9 increased by 123 seconds ( $P=.02$ ) and peak walking time by 104 seconds ( $P=.01$ ). The calf raise  
10 group increased the enzyme citrate synthase activity, which is a biomarker of mitochondrial  
11 volume-density in the muscle tissue ( $P=.02$ ). The walking group did not increase any of these  
12 variables. Maximal blood flow, peak oxygen uptake and mitochondrial respiration did not  
13 change in either groups. The calf raise group experienced less disease anxiety ( $P<.01$ ).  
14 Adherence to the instruction of exercise was 100% in the calf raise group and 80% in the  
15 walking group. The calf raise group maintained physical activity. A reduction in activity ( $P<.01$ )  
16 was found in the walking group.

17 Conclusion:Calf raise exercise improves walking performance and increases mitochondrial  
18 volume-density in the gastrocnemius muscle without increasing blood flow in patients with  
19 intermittent claudication.

20

## 21 **Introduction:**

22 Patients with intermittent claudication (IC) experience muscle ischemia during walking that is  
23 felt as cramping and aching in the affected muscle.<sup>1</sup> The prevalence of IC increases with age and

1 the number of patients with IC can be expected to increase further as the population of Europe  
2 and North America is aging.<sup>2,3</sup> Thereby, IC will lead to an increased burden for healthcare  
3 systems in the years to come. Patients with IC can benefit from exercise training, besides  
4 medical treatment, smoking cessation and interventions.<sup>4</sup> Supervised exercise programs are  
5 efficient, but the number of patients with IC makes it difficult to offer this type of training to  
6 everybody.<sup>5</sup> Structured home-based exercise programs also improve walking performance, but  
7 are less efficient.<sup>6,7</sup> To meet future demands, efficient and manageable home-based exercise  
8 programs are needed.

9 A hallmark of IC is ischemia due to reduced blood flow. Research also supports that patients  
10 with IC have reduced enzyme activity and respiratory defects in the muscle mitochondria.<sup>8-10</sup>  
11 Patients with IC seem to increase mitochondrial capacity after exercise training without  
12 increasing blood flow.<sup>11,12</sup> Exercise training till onset of ischemia is recommended for maximal  
13 effect in these patients.<sup>1,13</sup> Such training-induced ischemia followed by reperfusion, provokes  
14 preconditioning, which improves mitochondrial capacity both in skeletal muscle and heart  
15 muscle.<sup>14,15</sup>

16 The aim of the present study was therefore to test whether exposure to a single episode of  
17 instruction for daily training without supervision using preconditioning could improve walking  
18 performance and mitochondrial capacity in patients with IC, without increasing blood flow.

## 1 **Methods**

2 **Patient screening.** A total of twenty-nine PAD patients limited by intermittent claudication were  
3 enrolled into this study. The patients were recruited between February 2015 and January 2016 at  
4 the Department of Vascular Surgery, St Olavs University Hospital, Trondheim, Norway. All  
5 experimental protocols and procedures were approved by the regional committee of medical and  
6 health research ethics, central Norway (nr. 2011/2533) and conformed to the Declaration of  
7 Helsinki. Written informed consent was obtained from all participants. The study was registered  
8 in ClinicalTrials.gov (ID: NCT 023110256).

9 All patients had a physical examination and medical history during baseline visit and  
10 were classified by the following criteria: (1) a history of intermittent claudication, (2) exercise  
11 tolerance limited by intermittent claudication during a screening treadmill test, (3) an ankle  
12 brachial index (ABI) at rest above 0.4 and below 0.9, (4) No age restrictions were applied and (5)  
13 vascular interventions over three months independent of indication (also critical limb ischemia)  
14 but resulting in stable intermittent claudication symptoms, which were of no hindrance.  
15 Patients were excluded from this study having (1) absence of PAD, (2) asymptomatic PAD, (3)  
16 critical limb ischemia; defined as those with ABI below 0.4 combined with rest pain or ischemic  
17 ulcer, (4) exercise tolerance limited by factors other than claudication (eg, coronary artery  
18 disease, dyspnea), (5) vascular interventions in the last three months, (6) usage of antiplatelet  
19 drug other than acetylsalicylic acid (eg, Plavix, Persantine), (7) usage of anticoagulants (eg,  
20 Warfarin), (8) diabetes mellitus, (9) active cancer and (10) renal- or liver disease which needed  
21 treatment or follow up.

22 **Procedures.** Patients were evaluated during study visits at baseline and after eight weeks  
23 of the exercise intervention. During each visit, patients completed tests in the following order:

1 (1) physical examination including a review of current medication (2) questionnaires on quality  
2 of life and physical function; (3) collection of muscle biopsies (4) exercise and physical function  
3 test; (5) peripheral hemodynamics tests. During the baseline visit it was determined whether  
4 patients could comply with the exercise interventions and perform cardiopulmonary testing.  
5 At the end of the baseline visit participants were randomized (Figure 1) between a calf raise  
6 exercise group (n=14) or a walking exercise group (n=15). An internet-based randomization  
7 database using a 1:1 allocation, offered by the Unit for Applied Clinical Research at our Medical  
8 Faculty was used. Assessors were blinded to the allocation of each participant.  
9 There were no complications as a result of the exercise interventions. Two patients were  
10 excluded from analysis in the walking group; one patient suffered of a partial gastrocnemius  
11 muscle rupture on the day after the baseline testing and one patient developed critical ischemia  
12 and needed surgery.

13

14 **Exercise interventions.** The calf raise exercise group was instructed to perform calf raise  
15 exercise three times a day. Calf raise exercise consisted of the subject standing in front of a wall,  
16 which was used for support of the balance. The body was lifted using the calve muscles to the  
17 maximal height that the subject could achieve. This was repeated until pain was felt in the calf  
18 musculature. Following initiation of pain, the subject was instructed to perform five extra calf  
19 raises. The five extra calf raises secured ischemia followed by reperfusion of the muscle at rest.  
20 Thereby establishing a preconditioning situation. The exercise training was entitled “Five plus”.  
21 The walking exercise group was instructed to walk near the pain threshold for 30 minutes, three  
22 times a week.  
23 Both training regimens were home-based and without supervision for eight weeks.

1 No instructions were given on risk factor management or lifestyle modification to any of the two  
2 groups. It is normal practice at the vascular clinic that instruction in exercise is only provided  
3 once to patients, and it was the intent of the current study to reproduce this practice. We were  
4 mainly interested in the improvements after one single instruction of exercise and not the effect of  
5 different types of exercise. The latter would have needed supervision to guarantee adherence.

## 6 **Adherence**

7 An activity monitor (Garmin Vivofit) was placed on the arm, which was worn for the whole  
8 study period. This was done to monitor compliance. Furthermore, a training diary was given to  
9 the participants. The calf raise group registered the amount of calf raises performed during each  
10 session. The walking group registered the time and content of each activity. Participants in both  
11 groups registered each evening the total counts of activity registered by the monitor. Comparison  
12 of the average counts of activity per day in the first week was compared to the average count of  
13 the last week. Adherence was based on whether participants followed the instruction of exercise.

14

## 15 **Measurements**

### 16 **Walking performance and oxygen uptake**

17 **6-minute walk test.** A standardised protocol was followed.<sup>16</sup> The self-paced six-minute  
18 walk test assessed the pain free walking distance as the distance at which participants first  
19 reported pain and the distance covered during six minutes.

20 Maximal walking distance was the distance at which participants stopped because of  
21 claudication pain.

22 **Cardio Pulmonary Exercise Testing (CPET).** A treadmill (Woodway, USA) with a  
23 graded Gardner-Skinner protocol consisting of a constant speed of  $3.2 \text{ km} \cdot \text{h}^{-1}$  was used for

1 cardio pulmonary testing together with the device METAMAX II and the METASOFT software  
2 (Cortex, Germany).<sup>17</sup> The inclination started at 0%, and increased by 2% every second minute  
3 until the end of the test. Peak oxygen uptake ( $VO_{2peak} = \text{ml /kg/min}$ ) was determined as being the  
4 highest value obtained.

5 Claudication onset time was the onset of claudication pain and peak walking time was the time at  
6 which participants stopped the test, during the tests on the treadmill.

7

## 8 **Peripheral hemodynamics**

9 **Ankle Brachial Index.** Ankle brachial index, an evaluation of blood pressures in the arm  
10 and the ankle was performed at rest.<sup>18</sup>

11 **Plethysmography:** Plethysmography assessments were conducted as previously  
12 described.<sup>19</sup> The blood flow in the lower extremity was assessed with a strain-gauge  
13 plethysmography (Hokanson A16 Inc, Bellevue).

14 To assess maximal hyperemic response to ischemia (ml/100ml/min) to the calf the thigh cuff was  
15 inflated to 220 mmHg for five minutes, resulting in total arterial and venous occlusion of the leg.  
16 During the last minute of arterial occlusion, the ankle cuff was, as above, inflated to 250 mmHg.  
17 The thigh cuff was deflated to initiate reactive hyperaemia. A series of ten to 15 measurements  
18 was performed during which each measurement the thigh cuff was again inflated for ten seconds  
19 at 40 mmHg to block the venous reflux. Thereby the arterial inflow to the calves was measured  
20 at rest and as a maximal response in the hyperaemic phase.

21

## 22 **Mitochondrial function**

1           **Muscle biopsy.** Biopsies were collected from the lateral part of the gastrocnemius  
2 muscle. A micro biopsy technique was conducted to obtain muscle tissue as previously  
3 described.<sup>20 21</sup>

4           **Permeabilized skeletal muscle fiber preparation.** The muscle tissue was treated, in  
5 order1 to permeabilize the extracellular membranes of the muscle fibers leaving intracellular  
6 membranes of the mitochondria intact.<sup>21,22</sup> The wet weight of muscle fibers (1-3mg) was  
7 measured on a microbalance (Sartorius ME235P-SD; Sartorius AG, Goettingen, Germany)  
8 immediately before assessment of mitochondrial respiration.

9           **Mitochondrial respirometry.** The muscle fibers were analyzed by high-resolution  
10 respirometry measurements (Oxygraph-2k; Oroboros Instruments, Innsbruck, Austria). The  
11 oxygen concentration and oxygen consumption were continuously recorded in the chamber.  
12 Oxygen consumption per second, per milligram of wet weight of muscle fibers was addressed as  
13 mitochondrial respiration ( $\text{pmol O}_2 / \text{s} / \text{mg}$  wet weight of muscle fibers). Measurements were  
14 performed at 37°C. All experiments were carried out in hyper-oxygenated chambers (250-500  
15  $\mu\text{M}$  oxygen).. The Substrate, Uncoupler and Inhibitor Titration (SUIT) protocol was used to  
16 examine different branches of the electron transfer system as previously described.<sup>21-23</sup> This  
17 was achieved by adding inductive or blocking substrates to the chamber. All respirometric  
18 analyses were made in duplicates. The LEAK state (presented with subscript <sub>L</sub>) represents the  
19 resting mitochondrial respiration of an unaltered and intact electron transport system in the  
20 absence of ADP. The LEAK state is measured from the electron flow through complex I (CI)  
21 and electron transferring flavoprotein (ETF). Convergent electron flow into the Q-junction from  
22 both complex I (CI) and ETF(ETF+CI)<sub>L</sub>. was induced with the addition of octanoylcarnitine (0.2  
23 mM) and malate (2 mM)



1 OXPHOS state (presented with subscript  $_P$ ) represents maximal electron flow through the  
2 electron transfer system in the presence of ADP. Electron transferring-flavoprotein capacity  
3  $(ETF+CI)_P$  was determined following the addition of ADP (5 mM). Mitochondrial respiration  
4 specific to complex I  $(CI+ETF)_P$  was induced by the addition of glutamate (10 mM). Respiration  
5 supported by complex I and complex II  $(CI+CII+ETF)_P$ , was then induced with the addition of  
6 succinate (10 mM).  $(CI+CII+ETF)_P$ .<sup>22</sup>

7 Electron transfer system (presented with subscript  $_E$ ) state represents the electron transport  
8 through the electron transfer system, when it is uncoupled from ATPase (complex V). Electron  
9 transfer system capacity  $(CI+CII+ETF)_E$  was assessed through titration of the proton ionophore,  
10 carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP: 0.5 M stepwise titration to  
11 optimum concentrations ranging from 1.5 to 3 M). Rotenone (0.5 M) was added to inhibit  
12 complex I, thereby electron flow specific to complex II  $(CII)_E$  can be measured. Finally, malonic  
13 acid (5mM) and antimycin A (2.5 M) were added.

14 **Citrate synthase activity. (mitochondrial content)** Citrate synthase activity is a  
15 biomarker that is representative for the total concentration / volume-density of the mitochondria  
16 present in the muscle tissue.<sup>24</sup> Citrate synthase activity was assayed as previously described in  
17 homogenates of the permeabilized fibers used in the respiration measurements.<sup>21,23</sup>

18

19 **Health related Quality of life.**

20 **Short Health Form 36 Survey (SF36):** Self-reported physical function was assessed  
21 with SF 36: consisting of the eight subscales: physical function, physical role, bodily pain,  
22 general health, vitality, social function, emotional role and mental health.

1           **Claudication Scale (CLAU-S):** Self-reported walking ability, specific for patients with  
2 intermittent claudication was assessed with CLAU-S: consisting of the five subscales: daily life,  
3 pain, social life, disease-specific anxiety and psychological wellbeing.

4 The scores of the SF-36 and CLAU-S were notified separately. Both SF-36 and CLAU-S are  
5 validated instruments.<sup>25,26</sup>

6  
7 **Statistical analyses.** The primary analysis was based on an intention to treat basis. Primary  
8 endpoints were maximal walking distance/peak walking time and mitochondrial respiration  
9 supported by electron transfer flavoprotein and complex I. Secondary endpoints were citrate  
10 synthase activity, maximal hyperemic response to ischemia, peak oxygen uptake and quality of  
11 life (CLAU-S and SF36).

12 The sample size was based on maximal walking distance/peak walking time data from previous  
13 studies<sup>6,13</sup> and unpublished data, from our group, on improvements in mitochondrial respiration  
14 after exercise in older adults. A two-sided significance level of .05 and a power of the test of  
15 80% indicated a need of 14 participants to be included in each group.

16 The primary objective of this study was to compare changes within each group (pre versus post).  
17 Comparisons within the groups before and after exercise were done using paired t-test. The  
18 randomization procedure was used to secure similar baseline characteristics. Continuous data  
19 were reported as the mean with standard deviation or as the mean with the standard error of the  
20 mean. Significance was considered at  $P$  value  $< .05$ . All analyses were performed using STATA  
21 13<sup>th</sup> edition (StataCorp LP, Texas, USA).

22

## 1 **Results**

### 2 **Demographics**

3 The randomization resulted in similar baseline clinical characteristics between the calf raise  
4 group and the walking group (Table I) except for that the calf raise group was heavier than the  
5 walking group.

### 6 **Walking performance**

7 The groups were similar at baseline on each measure of walking performance except for that the  
8 calf raise group had a shorter pain free walking distance. The calf raise group increased (Table  
9 II) pain free walking distance ( $P=.04$ ), maximal walking distance ( $P=.047$ ), claudication onset  
10 time ( $P=.02$ ) and peak walking time ( $P=.01$ ). No changes in walking performance were found  
11 in the walking group.

### 13 **Adherence**

14 Adherence to the instruction of exercise was 100% in the calf raise group and 80% in the  
15 walking group. The calf raise group maintained physical activity. A reduction in activity ( $P<.01$ )  
16 was found in the walking group. (Table II)

### 18 **Oxygen uptake and peripheral hemodynamics**

19 The groups were similar (Table III) at baseline on oxygen uptake, ankle brachial index and  
20 maximal hyperemic response to ischemia. Neither group had any significant change in these  
21 measures.

22

## 1 **Mitochondrial function**

2 The groups were similar at baseline on each measure of mitochondrial function. Mitochondrial  
3 respiration did not change within any group (Table IV). Citrate synthase activity increased  
4 ( $P=.02$ ) significantly within the calf raise group.

## 6 **Health related Quality of life.**

7 The groups were similar at baseline on each measure of quality of life (Table V and VI). The calf  
8 raise group increased the subscale `disease anxiety` ( $P<.01$ ), meaning that they experienced less  
9 anxiety.

## 10 Discussion

11  
12 Calf raise exercise with five extra repetitions, entitled “Five plus”, over a period of eight weeks  
13 improved walking performance, measured as maximal walking distance and peak walking time  
14 on a treadmill. Calf raise exercise increased citrate synthase activity, a biomarker of muscle  
15 mitochondrial volume-density, without changing mitochondrial respiration and maximal  
16 hyperemic response to ischemia in patients with intermittent claudication. No significant changes  
17 in walking performance, mitochondrial respiration, volume-density and blood flow were  
18 observed in the walking group.

19 Up to 20% of patients with peripheral arterial disease experience symptoms of intermittent  
20 claudication (IC).<sup>2</sup> The reduced walking performance in these patients results in reduced quality  
21 of life.<sup>26</sup> Patients with IC have a 2.5-fold increase in cardiovascular morbidity and mortality  
22 compared with an age-matched population.<sup>1</sup> Exercise training has shown to improve walking  
23 performance in patients with IC and to reduce cardiac risk and mortality.<sup>13,27</sup>

1 Introduction of supervised training programs are lacking in Europe and North America, even  
2 though supervised exercise is cost-effective.<sup>27-29</sup> The programs seem not to be feasible due to the  
3 number of individuals having IC. Some home-based exercise programs have shown to increase  
4 walking performance while others do not.<sup>6,7,25</sup> Walking advice alone has been compared with  
5 home-based structured exercise, and the latter has shown better results.<sup>6,7</sup> We propose a new  
6 home-based calf raise exercise training focusing on the metabolism in the leg muscles of interest,  
7 thereby excluding classical training goals as cardio-pulmonary function, but trying to improve  
8 the mitochondrial metabolism, through preconditioning. The training concept is easy to perform  
9 and self-regulatory since the instruction to perform five extra calf raises after debut of pain will  
10 remain unchanged with any improvement. It is of value that an exercise program without  
11 supervision is followed. Other home-based exercise programs showed an adherence of  
12 approximately 80%.<sup>6,7</sup> In contrary to this all the participants in the calf raise group adhered to  
13 the given instruction. Furthermore, the average age was higher and the ankle brachial index was  
14 lower in our calf raise group compared to the home-based studies. This supports that our calf  
15 raise exercise has an impact also in older individuals and in those that have a more severe PAD.  
16 But this study is not able to clarify whether the response differs in different age groups and  
17 different degrees of claudication intermittens.

18 The calf raise group had similar improvements in claudication onset time and peak walking time  
19 after eight weeks as the other home-based programs.<sup>6,7</sup> Claudication onset time and peak  
20 walking time are assessed on a treadmill with increased inclination during testing. Strength  
21 training programs<sup>30-32</sup> have shown similar improvements in walking performance as measured  
22 by treadmill. One can speculate whether calf raises exercise strengthens the leg muscle and  
23 thereby increases walking performance at steeper grounds. The walking group did not increase

1 claudication onset time and peak walking time after eight weeks. The structured home based  
2 exercise programs consisted of walking exercise and showed increases in these variables. The  
3 difference to our walking group was that participants were contacted several times by the  
4 investigators in order to control whether they adhered to the walking exercise. The calf raise  
5 group did not increase activity which is in line with the other home-based studies.<sup>6</sup> The walking  
6 group decreased their activity, which shows that instruction of walking exercise alone is not  
7 sufficient to maintain activity and external control is needed.

8 The pathophysiology of intermittent claudication is mainly explained as a result of the reduced  
9 blood flow. A meta-analysis could however not find any increase in blood flow after exercise  
10 training.<sup>33</sup> This is in accordance to our observations with no significant changes in blood flow in  
11 either groups. In patients with IC, besides reduced blood flow, metabolic changes in the muscle  
12 mitochondria also occur expressed as lower mitochondrial enzyme activity.<sup>8,9,34</sup> A more  
13 effective usage by the mitochondria of the oxygen that is delivered to the muscle might therefore  
14 be an alternative explanation to the improvement after exercise.<sup>35</sup> Exercise training of healthy  
15 elderly with normal blood flow increases muscle mitochondrial capacity.<sup>36</sup> Less is known about  
16 mitochondrial adaptations after exercise in patients with reduced blood flow.

17 We assessed mitochondrial respiration, being a functional assay of mitochondrial oxygen  
18 consumption of the complexes collectively during oxidative phosphorylation. This includes a  
19 direct analysis of complex I to IV. We did not find any increase in mitochondrial respiration.  
20 After dynamic leg exercise of patient with IC mitochondrial enzymes, that indirect reflect  
21 complex II (succinic oxidase activity) and complex IV function (cytochrome C oxidase)<sup>11,12</sup>  
22 have shown to increase. The only mitochondrial enzyme assessed in this study was citrate  
23 synthase activity, which was increased significantly in the calf raise group, but not in the walking

1 group. Increased citrate synthase activity after exercise of strength has previously been shown  
2 after exercise of strength in patients relatively and directly.<sup>11,37</sup> Our calf raise could therefore be  
3 characterized as an exercise of strength, possibly resulting in increased mitochondrial content.  
4 Others did not find changes in citrate synthase after walking exercise.<sup>38</sup> Walking exercise  
5 focuses on endurance, thereby possibly leading to increased mitochondrial efficiency of the  
6 mitochondria present and not leading to increased mitochondrial content.  
7 The six-minute walking distance did not change indicating that walking speed remained the  
8 same. Walking speed has been shown to correlate with mitochondrial ATP production.<sup>36</sup> The  
9 lack of change in mitochondrial respiration in our groups might mirror similar mitochondrial  
10 energy production per time unit resulting in unchanged walking speed. The increased  
11 mitochondrial content in the calf raise group might improve energy production over time  
12 resulting in an increased maximal walking distance and peak walking time at a similar walking  
13 speed. Further research is necessary to clarify the importance of endurance and strength exercise  
14 in patients with intermittent claudication and the resulting mitochondrial responses.  
15 Regarding quality of life a significant change in disease specific anxiety was found in the calf  
16 raise group. This supports the psychological value of home-based, self-regulated training.

#### 17 Limitations

18 This is a small study that requires replication in external sites with larger N and longer follow up  
19 to determine the external validity of the findings. The calf raise group was heavier at baseline  
20 and they had a lower pain free walking distance and claudication onset time. Thereby these  
21 patients might have been de-conditioned and have more to gain from exercise. Mitochondrial  
22 respiration was assessed under hyper-oxygenated conditions. Mitochondrial respiration assessed  
23 under hypoxic conditions might better represent the physiological adaptations that occur after an

1 exercise intervention. Diabetics were excluded because they differ in mitochondrial  
2 bioenergetics compared to non-diabetics and in relation to the degree of the disease which  
3 would have been an confounding factor.<sup>39</sup> The mitochondrial response to exercise might  
4 therefore differ in diabetics.

#### 5 Conclusion

6 Calf raise exercise improves walking performance. The training increases a biomarker of  
7 mitochondrial volume-density but not in mitochondrial respiration or maximal hyperemic  
8 response to ischemia. “Five plus” may be an easy, home-based and efficient exercise training for  
9 patients with IC as an alternative to the usual advice to “stop smoking and keep walking”.

10

#### 11 References

- 12 1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-Society  
13 Consensus for the Management of Peripheral Arterial Disease (TASC II). *Eur J Vasc*  
14 *Endovasc Surg.* 2007;33 Suppl 1(1):S1–75.
- 15 2. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al.  
16 A population-based study of peripheral arterial disease prevalence with special focus on  
17 critical limb ischemia and sex differences. *J Vasc Surg.* 2007 Jun;45(6):1185–91.
- 18 3. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al.  
19 Comparison of global estimates of prevalence and risk factors for peripheral artery disease  
20 in 2000 and 2010: a systematic review and analysis. *Lancet.* 2013 Oct  
21 19;382(9901):1329–40.
- 22 4. Fokkenrood HJP, Bendermacher BLW, Lauret GJ, Willigendael EM, Prins MH, Tejjink



- 1 JAW. Supervised exercise therapy versus non-supervised exercise therapy for intermittent  
2 claudication. Fokkenrood HJ, editor. *Cochrane Database Syst Rev.* 2013;8:CD005263.
- 3 5. Makris GC, Lattimer CR, Lavidia A, Geroulakos G. Availability of supervised exercise  
4 programs and the role of structured home-based exercise in peripheral arterial disease. *Eur*  
5 *J Vasc Endovasc Surg.* 2012 Dec;44(6):569–75.
- 6 6. Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM. Efficacy of quantified  
7 home-based exercise and supervised exercise in patients with intermittent claudication: a  
8 randomized controlled trial. *Circulation.* 2011 Feb 8;123(5):491–8.
- 9 7. Mays RJ, Hiatt WR, Casserly IP, Rogers RK, Main DS, Kohrt WM, et al. Community-  
10 based walking exercise for peripheral artery disease: An exploratory pilot study. *Vasc*  
11 *Med.* 2015 Aug;20(4):339–47.
- 12 8. Brass EP, Hiatt WR, Gardner AW, Hoppel CL. Decreased NADH dehydrogenase and  
13 ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease. *Am J Physiol Heart*  
14 *Circ Physiol.* 2001 Feb;280(2):H603–9.
- 15 9. Pipinos II, Sharov VG, Shepard AD, Anagnostopoulos PV, Katsamouris A, Todor A, et al.  
16 Abnormal mitochondrial respiration in skeletal muscle in patients with peripheral arterial  
17 disease. *J of Vasc Surg.* 2003rd ed. 2003 Oct;38(4):827–32.
- 18 10. Pipinos II, Judge AR, Zhu Z, Selsby JT, Swanson SA, Johanning JM, et al. Mitochondrial  
19 defects and oxidative damage in patients with peripheral arterial disease. *Free Rad Biol*  
20 *Med.* 2006 Jul 15;41(2):262–9.

- 1 11. Lundgren F, Dahllöf AG, Scherstén T, Bylund-Fellenius AC. Muscle enzyme adaptation  
2 in patients with peripheral arterial insufficiency: spontaneous adaptation, effect of  
3 different treatments and consequences on walking performance. *Clin Sci*. 1989  
4 Nov;77(5):485–93.
- 5 12. Holm J, Dahllöf AG, Björntorp P, Scherstén T. Enzyme studies in muscles of patients  
6 with intermittent claudication. Effect of training. *Scand J Clin Lab Invest Suppl*.  
7 1973;128:201–5.
- 8 13. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of  
9 claudication pain. A meta-analysis. *JAMA*. 1995 Sep 27;274(12):975–80.
- 10 14. Thaveau F, Zoll J, Rouyer O, Chafke N, Kretz JG, Piquard F, et al. Ischemic  
11 preconditioning specifically restores complexes I and II activities of the mitochondrial  
12 respiratory chain in ischemic skeletal muscle. *J Vasc Surg*. 2007 Sep;46(3):541–7.
- 13 15. Slagsvold KH, Rognmo O, Høydal M, Wisløff U, Wahba A. Remote ischemic  
14 preconditioning preserves mitochondrial function and influences myocardial microRNA  
15 expression in atrial myocardium during coronary bypass surgery. *Circ Res*. 2014 Feb  
16 28;114(5):851–9.
- 17 16. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.  
18 ATS statement: guidelines for the six-minute walk test. Vol. 166, *Am J of Respir and Crit*  
19 *Care Med*. 2002. pp. 111–7.
- 20 17. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise  
21 conditioning for patients with peripheral arterial disease. *Circulation*. 1990

- 1 Feb;81(2):602–9.
- 2 18. McDermott MM, Liu K, Guralnik JM, Mehta S, Criqui MH, Martin GJ, et al. The ankle  
3 brachial index independently predicts walking velocity and walking endurance in  
4 peripheral arterial disease. *J Am Geriatr Soc.* 1998 Nov;46(11):1355–62.
- 5 19. Alomari MA, Solomito A, Reyes R, Khalil SM, Wood RH, Welsch MA. Measurements of  
6 vascular function using strain-gauge plethysmography: technical considerations,  
7 standardization, and physiological findings. *Am J Physiol Heart Circ Physiol.* 2004  
8 Jan;286(1):H99–H107.
- 9 20. Hayot M, Michaud A, Koechlin C, Caron M-A, LeBlanc P, Prefaut C, et al. Skeletal  
10 muscle microbiopsy: a validation study of a minimally invasive technique. *Eur Respir J.*  
11 2005 Mar;25(3):431–40.
- 12 21. van Schaardenburgh M, Wohlwend M, Rognmo O, Mattsson EJR. Mitochondrial  
13 Respiration after One Session of Calf Raise Exercise in Patients with Peripheral Vascular  
14 Disease and Healthy Older Adults. *PLoS ONE.* 2016;11(10):e0165038.
- 15 22. Pesta D, Gnaiger E. High-resolution respirometry: OXPHOS protocols for human cells  
16 and permeabilized fibers from small biopsies of human muscle. Moreno AJ, Palmeira CM,  
17 editors. Totowa, NJ: Humana Press; 2012;810(Chapter 3):25–58.
- 18 23. Jacobs RA, Lundby C. Mitochondria express enhanced quality as well as quantity in  
19 association with aerobic fitness across recreationally active individuals up to elite athletes.  
20 *J Appl Physiol.* A2013 Feb;114(3):344–50.

- 1 24. Larsen S, Nielsen J, Hansen CN, Nielsen LB, Wibrand F, Stride N, et al. Biomarkers of  
2 mitochondrial content in skeletal muscle of healthy young human subjects. *J Physiol* 2012  
3 Jul 15;590(Pt 14):3349–60.
- 4 25. Collins TC, Lunos S, Carlson T, Henderson K, Lightbourne M, Nelson B, et al. Effects of  
5 a home-based walking intervention on mobility and quality of life in people with diabetes  
6 and peripheral arterial disease: a randomized controlled trial. *Diabetes care*. 2011  
7 Oct;34(10):2174–9.
- 8 26. Mehta T, Venkata Subramaniam A, Chetter I, McCollum P. Assessing the validity and  
9 responsiveness of disease-specific quality of life instruments in intermittent claudication.  
10 *Eur J of Vasc Endovasc Surg*. 2006 Jan;31(1):46–52.
- 11 27. Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training  
12 for the primary and secondary prevention of cardiovascular disease. *J Cardiopulm*  
13 *Rehabil*. 2000 May;20(3):147–55.
- 14 28. Makris GC, Lattimer CR, Lavida A, Geroulakos G. Availability of supervised exercise  
15 programs and the role of structured home-based exercise in peripheral arterial disease. *Eur*  
16 *J Vasc Endovasc Surg*. 2012 Dec;44(6):569–76.
- 17 29. van Asselt ADI, Nicolai SPA, Joore MA, Prins MH, Teijink JAW, Exercise Therapy in  
18 Peripheral Arterial Disease Study Group. Cost-effectiveness of exercise therapy in  
19 patients with intermittent claudication: supervised exercise therapy versus a “go home and  
20 walk” advice. *Eur J Vasc Endovasc Surg*. 2011 Jan;41(1):97–103.
- 21 30. McGuigan MR, Bronks R, Newton RU, Sharman MJ, Graham JC, Cody DV, et al.

- 1 Resistance training in patients with peripheral arterial disease: effects on myosin isoforms,  
2 fiber type distribution, and capillary supply to skeletal muscle. *J Gerontol A Biol Sci Med*  
3 *Sci.* 2001 Jul;56(7):B302–10.
- 4 31. Ritti-Dias RM, Wolosker N, de Moraes Forjaz CL, Carvalho CRF, Cucato GG, Leão PP,  
5 et al. Strength training increases walking tolerance in intermittent claudication patients:  
6 randomized trial. *J of Vasc Surg.* 2010 Jan;51(1):89–95.
- 7 32. Wang E, Hoff J, Loe H, Kaehler N, Helgerud J. Plantar flexion: an effective training for  
8 peripheral arterial disease. *Eur J Appl Physiol.* 2008 2008 Nov;104(4):749–56.
- 9 33. Parmenter BJ, Raymond J, Fiatarone Singh MA. The effect of exercise on  
10 haemodynamics in intermittent claudication: a systematic review of randomized  
11 controlled trials. *Sports Med.* 2010 May 1;40(5):433–47.
- 12 34. Bylund AC, Hammarsten J, Holm J, Scherstén T. Enzyme activities in skeletal muscles  
13 from patients with peripheral arterial insufficiency. *Eur J Clin Invest.* 1976 Nov  
14 30;6(6):425–9.
- 15 35. Egan B, Zierath JR. Exercise Metabolism and the Molecular Regulation of Skeletal  
16 Muscle Adaptation. *Cell Metab.* 2013 Feb;17(2):162–84.
- 17 36. Coen PM, Jubrias SA, Distefano G, Amati F, Mackey DC, Glynn NW, et al. Skeletal  
18 muscle mitochondrial energetics are associated with maximal aerobic capacity and  
19 walking speed in older adults. *J Gerontol A Biol Sci Med Sci.* 2013 Apr;68(4):447–55.
- 20 37. Balakrishnan VS, Rao M, Menon V, Gordon PL, Pilichowska M, Castaneda F, et al.

1           Resistance training increases muscle mitochondrial biogenesis in patients with chronic  
2           kidney disease. *Clin J Am Soc Nephrol*. 2010 Jun;5(6):996–1002.

3   38.   Hou XY, Green S, Askew CD, Barker G, Green A, Walker PJ. Skeletal muscle  
4           mitochondrial ATP production rate and walking performance in peripheral arterial  
5           disease. *Clin Physiol Funct Imaging*. 2002 May;22(3):226–32.

6   39.   Phielix E, Mensink M. Type 2 diabetes mellitus and skeletal muscle metabolic function.  
7           *Physiol Behav*. 2008 May 23;94(2):252–8.

8

9

1

2 **Table I:** Baseline clinical characteristics of patients with intermittent claudication who

3 participated in a calf raise group and a walking group

	Calf raise group		Walking group	
	(n=14)		(n=13)	
	mean (SD)	range	mean (SD)	range
Female sex, n	7		6	
Age	66 (9.3)	46-86	70 (8.2)	52-77
Height	171 (6)	160-180	170 (9)	159- 187
Weight	80 (11)	64-100	72 (11)	57-97
Ankle brachial index	0.58 (0.11)	0.41- 0.77	0.57 (0.21)	0.32- 0.93
Systolic blood pressure	143 (22)	115-180	145 (21)	120- 190
Diastolic blood pressure	82 (13)	60-110	82 (6)	70-95
Drug therapy				
• Statin, n	8		8	
• Acetylsalicylic acid, n	9		10	
Comorbidity				
• Previous peripheral vascular intervention, n	4		6	

- Previous myocardial infarction/ intervention, n 2 2
- Current smoker, n 3 5
- Previous smoker, n 6 5

---

1 SD = standard deviation, n=number

2

3



1 **Table II:** Walking performance in patients with intermittent claudication who performed calf  
 2 raise exercise (n=14) or walking exercise (n=13)

3

<i>Variables</i>	<i>Pre-test</i>	<i>Post-test</i>	<i>Change</i>	<i>P value</i>
	mean (SEM)	mean (SEM)	mean (SEM)	
<b>Pain free walking distance</b>				
<b>(m)</b>				
Calf raise group	177 (18)	221 (22)	44 (22)	.04
Walking group	305 (108)	352 (62)	46 (115)	.34
<b>Maximal walking distance</b>				
<b>(m)</b>				
Calf raise group	535 (39)	634 (85)	98 (54)	.047
Walking group	619 (68)	700 (145)	74 (108)	.25
<b>6 minute walking distance</b>				
<b>(m)</b>				
Calf raise group	466 (14)	480 (17)	15 (11)	.11
Walking group	452 (14)	462 (14)	10 (15)	.27
<b>Claudication onset time</b>				
<b>(sec)</b>				
Calf raise group	255 (45)	378 (61)	123 (51)	.02
Walking group	309 (31)	354 (59)	45 (48)	.19
<b>Peak walking time (sec)</b>				

Calf raise group	709 (98)	813 (113)	104 (39)	.01
Walking group	595 (64)	610 (66)	15 (43)	.37

**Activity monitor (counts  
per day) <sup>b</sup>**

Calf raise group	9170 (974)	9567 (1029)	396 (458)	.21
Walking group	7238 (1278)	6271 (1174)	-967(299)	<.01

---

1 SEM = standard error of the mean

2

3

4

- 1 **Table III:** Peak oxygen uptake and peripheral hemodynamics in patients with intermittent  
 2 claudication who performed calf raise exercise (n=14) or walking exercise (n=13)

<i>Variables</i>	<i>Pre-test</i>	<i>Post-test</i>	<i>Change</i>	<i>P</i>
	mean	mean	mean	
	(SEM)	(SEM)	(SEM)	<i>value</i>
<b>Peak Oxygen uptake (ml/kg/min)</b>				
Calf raise group	18.7 (1.5)	19.0 (1.6)	0.4 (0.5)	.24
Walking group	18.1 (0.8)	17.9 (0.8)	- 0.2 (0.9)	.57
<b>Ankle Brachial Index</b>				
Calf raise group	0.58 (0.03)	0.58 (0.03)	0.00 (0.03)	.91
Walking group	0.57 (0.06)	0.57 (0.05)	0.00 (0.04)	.95
<b>Maximal hyperemic response to ischemia (ml/100ml/min)</b>				
Calf raise group	11.8 (1.2)	11.6 (1.4)	0.23 (0.4)	.29
Walking group	10.0 (1.3)	10.0 (1.4)	-0.01 (0.4)	.51

3 SEM = standard error of the mean

4

1 **Table IV:** Mitochondrial function: mitochondrial respiration (pmol/mg/s) and citrate synthase  
 2 activity ( $\mu\text{mol}/\text{min}/\text{mg}$  of protein) in patients with intermittent claudication who performed calf  
 3 raise exercise (n=14) or walking exercise (n=13)

4

<i>Variables</i>	<i>Pre-test</i>	<i>Post-test</i>	<i>Change</i>	<i>P value</i>
	mean (SEM)	mean (SEM)	mean (SEM)	
<b>Respiration supported by (ETF+CI)<sub>L</sub></b>				
Calf raise group	10.1 (1.2)	9.6 (0.8)	-0.5 (1.5)	
Walking group	10.7 (0.6)	10.2 (1.3)	-0.5 (1.2)	
<b>Respiration supported by (ETF+CI)<sub>P</sub></b>				
Calf raise group	18.9 (1.5)	17.2 (2.7)	-1.7 (2.2)	
Walking group	20.3 (0.6)	19.6 (1.8)	-0.7 (1.5)	
<b>Respiration supported by (CI+ETF)<sub>P</sub></b>				
Calf raise group	36.1 (1.8)	33.9 (2.5)	-2.2 (2.2)	
Walking group	39.7 (3.2)	38.1 (3.2)	-1.6 (1.9)	
<b>Respiration supported by (CI+CII+ETF)<sub>P</sub></b>				
Calf raise group	70.8 (4.2)	66.4 (4.7)	-4.4 (3.4)	
Walking group	74.8 (5.7)	70.1 (5.5)	-4.7 (3.5)	
<b>ETS capacity supported by (CI+CII+ETF)<sub>E</sub></b>				
Calf raise group	87.6 (5.4)	85.2 (7.3)	-2.4 (6.6)	
Walking group	95.7 (7.8)	90.3 (8.4)	-5.4 (4.7)	
<b>Respiration supported by (CII)<sub>E</sub></b>				
Calf raise group	51.2 (2.9)	50.3 (3.7)	-0.9 (3.9)	

Walking group	52.6 (4.6)	53.7 (3.8)	1.1 (3.7)
<b>Citrate synthase activity</b>			
Calf raise group	4.74 (0.1)	4.82 (0.12)	0.08 (0.03)
Walking group	4.80 (0.07)	4.88 (0.2)	0.08 (0.06)

---

- 1
- 2 ETF = Electron Transferring Flavoprotein; CI = Complex I, CII = Complex II, ETS = Electron
- 3 transfer system; The subscripts L,P,E indicate the LEAK state, (OX) PHOS state and ETS
- 4 capacity. SEM = standard error of the mean.

- 1 **Table V:** Health related quality of Life measured by the questionnaires SF-36 in patients with  
 2 intermittent claudication who performed calf raise exercise (n=14) or walking exercise (n=13).

<i>Variables</i>	<i>Pre-test</i>	<i>Post-test</i>	<i>Change</i>	<i>P value</i>
	mean (SEM)	mean (SEM)	mean (SEM)	
<b>SF 36</b>				
<b>Pain</b>				
Calf raise group	59.0 (6.4)	62.3 (5.7)	3.3 (6.1)	.31
Walking group	57.7 (6.6)	60.0 (6.3)	2.3 (8.6)	.40
<b>General health</b>				
Calf raise group	77.9 (4.5)	72.6 (4.6)	-5.3 (4.5)	.13
Walking group	58.5 (3.8)	64.2 (5.7)	5.7 (4.3)	.11
<b>Vitality</b>				
Calf raise group	59.4 (4.6)	57.8 (3.1)	-1.6 (3.2)	.32
Walking group	59.1 (3.9)	62.0 (6.4)	2.9 (6.7)	.33
<b>Mental health</b>				
Calf raise group	82.2 (4.3)	84.2 (3.2)	1.9 (2.4)	.22
Walking group	75.0 (5.0)	80.9 (5.0)	5.9 (7.4)	.22
<b>Social function</b>				
Calf raise group	87.5 (4)	87.5 (4.5)	0 (3.5)	1.00
Walking group	85.0 (5.2)	91.3 (4.2)	6.3 (5.7)	.11
<b>Emotional role</b>				
Calf raise group	80.1 (6.9)	85.3 (6.9)	5.1 (8.5)	.28
Walking group	77.1(8.7)	81.3 (8.7)	4.2 (6.5)	.27

**Physical function**

Calf raise group	64.2 (4.9)	64.2 (2.8)	0 (3.2)	1.00
Walking group	64.2 (4.1)	6.7 (4.9)	2.9 (4.2)	.25

**Physical role**

Calf raise group	68.3 (6.8)	74.5(5.0)	6.3 (5.2)	.13
Walking group	61.4 (6.9)	67.2 (6.9)	5.7 (7.3)	.22

---

1 SEM = standard error of the mean

2

1 **Table VI:** Disease specific quality of Life measured by the questionnaires CLAU-S in patients  
 2 with intermittent claudication who performed calf raise exercise (n=14) or walking exercise  
 3 (n=13).

<i>Variables</i>	<i>Pre-test</i>	<i>Post-test</i>	<i>Change</i>	<i>P value</i>
	mean (SEM)	mean (SEM)	mean (SEM)	
<b>CLAU-S</b>				
<b>Pain</b>				
Calf raise group	59.6 (2.9)	57.1 (4.0)	-2.5 (3.3)	.23
Walking group	61.1 (5.3)	63.5 (5.5)	2.3 (6.8)	.37
<b>Daily life</b>				
Calf raise group	73.7 (5.6)	73.4 (5.4)	- 0.3 (3.1)	.10
Walking group	76.4 (4.3)	69.0 (6.5)	- 7.4 (5.5)	.47
<b>Social life</b>				
Calf raise group	93.8 (1.4)	95.2 (2.5)	1.4 (2.0)	.25
Walking group	90.1 (4.3)	90.1 (3.6)	0.0 (2.4)	1.00
<b>Disease Anxiety</b>				
Calf raise group	75.6 (5.9)	85.7 (5.7)	9.1 (2.3)	<.01
Walking group	74.8 (5.0)	80.9 (7.8)	6.2 (8.8)	.25
<b>Psychological wellbeing</b>				
Calf raise group	83.7 (2.7)	83.7 (2.8)	0.4 (3.5)	.46
Walking group	87.6 (3.1)	84.7 (5.5)	-2.9 (4.6)	.27

4 SEM = standard error of the mean

5



1

2